|
"hsu chiun"的相关文件
显示项目 56-105 / 149 (共3页)
<< < 1 2 3 > >>
每页显示[10|25|50]项目
| 國立臺灣大學 |
2013 |
Survival of patients receiving radiofrequency ablation or ethanol injection for early-stage hepatocellular carcinoma.
|
Lin, Zhong-Zhe; Shau, Wen-Yi; Shao, Yu Yun; Yeh, Yi-Chun; Kuo, Raymond Nien-Chen; Hsu, Chiun; Hsu, Chih-Hung; Cheng, Ann-Lii; Lai, Mei-Shu; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 徐志宏; 許駿; 郭年真 |
| 國立臺灣大學 |
2013 |
Potential synergistic antitumor activity between sorafenib and lenalidomide in an orthotopic murine liver cancer model.
|
Chang, Chun-Jung; Ou, Da-Liang; Lin, Yi-Jang; Cheng, Ann-Lii; Hsu, Chiun; 張純榮; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2012 |
PHASE II STUDY OF CONCOMITANT THALIDOMIDE DURING RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA
|
Ch' ang, Hui-Ju; Hsu, Chiun; Chen, Chien-Hung; Chang, Ya-Hui; Chang, Jeffrey S.; Chen, Li-Tzong; 許駿; 陳健弘 |
| 國立臺灣大學 |
2012 |
Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma
|
Shao, Yu-Yun; Lin, Zhong-Zhe; Hsu, Chiun; Lee, Kuan-Der; Hsiao, Chi-Huang; Lu, Yen-Shen; Huang, Chien-Chung; Shen, Yin-Chun; Hsu, Chih-Hung; Cheng, Ann-Lii; 盧彥伸; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 許駿 |
| 國立臺灣大學 |
2012 |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Hsu, Chiun; Yang, Tsai-Sheng; Huo, Teh-Ia; Hsieh, Ruey-Kuen; Yu, Chih-Wei; Hwang, Wei-Shou; Hsieh, Tsai-Yuan; Huang, Wen-Tsung; Chao, Yee; Meng, Robin; Cheng, Ann-Lii; 鄭安理; 許駿; 游治維 |
| 國立臺灣大學 |
2012 |
A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression
|
Shen, Ying-Chun; Hsu, Chiun; Cheng, Chia-Chi; Hu, Fu-Chang; Cheng, Ann-Lii; 鄭安理; 許駿; 胡賦強 |
| 國立臺灣大學 |
2012 |
Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy
|
Lin, Zhong-Zhe; Hsu, Chiun; Hu, Fu-Chang; Shao, Yu-Yun; Chang, Dwan-Ying; Yang, Chih-Hsin; Hong, Ruey-Long; Hsu, Chih-Hung; Cheng, Ann-Lii; 楊志新; 邵幼雲; 林宗哲; 鄭安理; 徐志宏; 洪瑞隆; 許駿; 胡賦強; 張端瑩 |
| 國立臺灣大學 |
2012 |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression
|
Hsu, Chiun; Shen, Ying-Chun; Cheng, Chia-Chi; Cheng, Ann-Lii; Hu, Fu-Chang; Yeh, Kun-Huei; 鄭安理; 許駿; 葉坤輝 |
| 國立臺灣大學 |
2012 |
Comparative microRNA detection from precursor-microRNA-transfected hepatocellular carcinoma cells by capillary electrophoresis with dual-color laser-induced fluorescence
|
Yang, Tzu-Hsueh; Ou, Da-Liang; Hsu, Chiun; Huang, Shih-Hua; Chang, Po-Ling; 歐大諒 |
| 國立臺灣大學 |
2012 |
Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma
|
Shau, Wen-Yi; Shao, Yu-Yun; Yeh, Yi-Chun; Lin, Zhong-Zhe; Kuo, Raymond; Hsu, Chih-Hung; Hsu, Chiun; Cheng, Ann-Lii; Lai, Mei-Shu; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 徐志宏; 許駿 |
| 國立臺灣大學 |
2011 |
Activation of Checkpoint Kinase 2 (Chk2) Contributes to the Antitumour Synergy between Igf1 Receptor Kinase Inhibitor Nvp-Aew541 and Sunitinib in Hepatocellular Carcinoma
|
歐大諒; 沈盈君; 許駿; 鄭安理; OU, DA-LIANG; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010-12 |
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B
|
Ko, Bor-Sheng; Chang, Tzu-Ching; Chen, Chien-Hung; Liu, Chia-Chia; Liang, Shu-Man; Hsing, En-Wei; Kuo, Cheng-Chin; Hsu, Chiun; Shen, Ying-Chun; Shen, Tang-Long; Shyue, Song-Kun; Golubovskaya, Vita M.; Chang, Chung-Che; Liou, Jun-Yang |
| 國立臺灣大學 |
2010 |
Bortezomib Suppresses Focal Adhesion Kinase Expression Via Interrupting Nuclear Factor-Kappa B
|
柯博升; 張孜菁; 陳建宏; 劉佳佳; 郭呈欽; 許駿; 沈盈君; 沈湯龍; 徐松錕; 劉俊揚; KO, BO-SHENG; CHANG, TZU-CHING; CHEN, CHIEN- HUNG; LIU, CHIA-CHIA; KUO, CHENG-CHIN; HSU, CHIUN; SHEN, YING-CHUN; SHEN, TANG-LONG; SHYUE, SONG-KUN; LIOU, JUN-YANG |
| 國立臺灣大學 |
2010 |
Adjuvant Interferon Therapy after Curative Therapy for Hepatocellular Carcinoma (Hcc): A Meta-Regression Approach
|
沈盈君; 許駿; 陳立宗; 鄭佳綺; 胡賦强; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; CHEN, LI-TZONG; CHENG, CHIA-CHI; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma
|
邵幼雲; 林宗哲; 許駿; 沈盈君; 徐志宏; 鄭安理; SHAO, YU-YUN; LIN, ZONG-ZHE; HSU, CHIUN; SHEN, YING-CHUN; HSU, CHIH-HUNG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Efficacy and Tolerability of Bevacizumab Plus Capecitabine as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
|
徐志宏; 許駿; 陳培哲; 林宗哲; 趙祖怡; 鄭安理; HSU, CHIH-HUNG; HSU, CHIUN; CHEN, PEI-JER; LIN, ZONG-ZHE; CHAO, TSU-YI; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (Dce-Mri) to Predict Treatment Outcomes for Advanced Hepatocellular Carcinoma (Hcc) Patients Who Received Sorafenib Plus Tegafur/Uracil Therapy
|
沈盈君; 許昭禹; 游治維; 許駿; 徐志宏; 鄭安理; 施庭芳; SHEN, YING-CHUN; HSU, CHAO-YU; YU, CHIH-WEI; HSU, CHIUN; HSU, CHIH-HUNG; CHENG, ANN-LII; SHIH, TIFFANY TING-FANG |
| 國立臺灣大學 |
2010 |
Geographic Difference in Survival Outcome for Advanced Hepatocellular Carcinoma: Implications on Future Clinical Trial Design
|
許駿; 沈盈君; 鄭佳綺; 胡賦强; 鄭安理; HSU, CHIUN; SHEN, YING-CHUN; CHENG, CHIA-CHI; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma: Current Status and Future Perspectives
|
沈盈君; 許駿; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Phase Ii Study of Combining Sorafenib with Metronomic Tegafur/Uracil for Advanced Hepatocellular Carcinoma
|
徐志宏; 沈盈君; 林宗哲; 陳培哲; 邵幼雲; 丁雅慧; 許駿; 鄭安理; HSU, CHIH-HUNG; SHEN, YING-CHUN; LIN, ZONG-ZHE; CHEN, PEI-JER; SHAO, YU-YUN; DING, YEA-HUI; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Predictive and Prognostic Values of Tau and Ercc1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin
|
邵幼雲; 郭冠廷; 胡賦强; 盧彥伸; 黃俊升; 廖肇裕; 許駿; 郭文宏; 張金堅; 林璟宏; 鄭安理; SHAO, YU-YUN; KUO, KUAN-TING; HU, FU-CHANG; LU, YEN-SHEN; HUANG, CHIUN-SHENG; LIAU, JAO-YU; HSU, CHIUN; KUO, WEN-HONG; CHANG, KING-JEN; LIN, CHING -HUNG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Preventive Effect of Anti-Viral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Meta -Regression Approach
|
鄭佳綺; 沈盈君; 許駿; 胡賦强; 鄭安理; CHENG, CHIA-CHI; SHEN, YING-CHUN; HSU, CHIUN; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Treatment Outcomes for Synchronous or Metachronous Hypopharyngeal/ Laryngeal/Oropharyngeal Cancer and Esophageal Cancer
|
許駿; 王駿瑋; 成佳憲; HSU, CHIUN; WANG, CHUN-WEI; CHENG, JASON CHIA-HSIEN |
| 國立臺灣大學 |
2010 |
Induction of DNA Damage-Inducible Gene Gadd45 Beta Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells
|
歐大諒; 沈盈君; 俞松良; 陳昆鋒; 葉培彥; 林亮音; 許駿; 鄭安理; OU DA-LIANG; SHEN YING-CHUN; YU SUNG-LIANG; CHEN KUEN-FENG; YEH PEI-YEN; LIN LIANG-IN; HSU CHIUN; CHENG ANN-LII |
| 國立臺灣大學 |
2010 |
Design, Translation, and Test of Multi-Dimensional Questionnaires
|
季瑋珠; 許駿; 章殷超; 程劭儀; 高芷華; CHIE, WEI-CHU; HSU, CHIUN; Y.C.CHANG; CHEN, G SHAO-YI; KAO, TZE-WAH |
| 國立臺灣大學 |
2010 |
Potentiating the Anti-Tumor Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Signaling Pathway
|
歐大諒; 許駿; 沈盈君; 鄭安理; OU, DA-LIANG; HSU, CHIUN; SHEN, YING-CHUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
The Aurora Kinase Inhibitor Ve-465 Has Anticancer Effects in Pre-Clinical Studies of Human Hepatocellular Carcinoma
|
許輝吉; 徐志宏; 葉培彥; 黃繼瑩; 郭頌鑫; 許駿; 胡賦強; 鄭永銘; 鄭安理; HSU, HEY-CHI; HSU, CHIH-HUNG; YEH, PEI-YEN; HUANG, CHI-YING; KUO, SUNG-HSIN; HSU, CHIUN; HU, FU-CHANG; JENG, YUNG-MING; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival
|
沈盈君; 胡賦強; 鄭永銘; 張毓廷; 林宗哲; 章明珠; 許駿; 鄭安理; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG-MING; CHANG, YU-TING; LIN, ZONG-ZHE; CHANG, MING-CHU; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Induction of Bim Expression Contributes to the Antitumor Synergy between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal- Regulated Kinase Kinase Inhibitor Ci-1040 in Hepatocellular Carcinoma
|
歐大諒; 沈盈君; 梁嘉德; 劉俊揚; 俞松良; 盧彥伸; 許駿; 鄭安理; OU, DA-LIANG; SHEN, YING-CHUN; LIANG, JA-DER; LIOU, JUN-YANG; YU, SUNG-LIANG; LU, YEN-SHEN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Overexpressed Focal Adhesion Kinase Predicts a Higher Incidence of Extrahepatic Metastasis and Worse Survival in Hepatocellular Carcinoma
|
詹以吉; 柯博升; 許駿; 王約翰; 劉俊揚; JAN, YEE-JEE; KO, BO-SHENG; HSU, CHIUN; WANG, JOHN; LIOU, JUN-YANG |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Bevacizumab (B) and Erlotinib (E) in Combination for Asian Patients (Pts) with Advanced/Metastatic Hepatocellular Carcinoma ( Hcc): An Interim Safety Report
|
徐志宏; 邱宗傑; 許駿; 鄭安理; HSU, CHIH-HUNG; CHIOU, TZEON-JYE; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Sorafenib in Combination with Tegafur/Uracil (Uft) for Asian Patients with Advanced Hepatocellular Carcinoma (Hcc)
|
沈盈君; 許駿; 徐志宏; 林宗哲; 陳培哲; 邵幼雲; 丁雅慧; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; HSU, CHIH-HUNG; LIN, ZONG-ZHE; CHEN, PEI-JER; SHAO, YU-YUN; DING, YEA-HUI; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
A Phase Ii Trial of Thalidomide Plus Tegafur/Uracil for Patients with Advanced/Metastatic Hepatocellular Carcinoma (Hcc): Final Report
|
徐志宏; 林宗哲; 沈盈君; 許駿; 鄭安理; HSU, CHIH-HUNG; LIN, ZONG-ZHE; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Adjuvant Interferon Therapy after Curative Therapy for Hepatocellular Carcinoma (Hcc): A Meta-Analysis
|
許駿; 沈盈君; 陳立宗; 胡賦强; 鄭安理; HSU, CHIUN; SHEN, YING-CHUN; CHEN, LI-TZONG; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Evaluation of Vandetanib in Patients with Inoperable Hepatocellular Carcinoma (Hcc): A Randomized, Double-Blind, Parallel Group, Multicentre, Phase Ii Study
|
許駿; 謝瑞坤; 黃偉修; 趙毅; 鄭安理; HSU, CHIUN; HSIEH, RUEY-KUN; HWANG, WEI-SHOU; CHAO, YEE; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Prognostic Factors of Survival in 236 Advanced Hepatocellular Carcinoma Patients Enrolled in Prospective Clinical Trials of Systemic Therapy
|
林宗哲; 邵幼雲; 徐志宏; 許駿; 洪瑞隆; 鄭安理; LIN, ZONG-ZHE; SHAO, YU-YUN; HSU, CHIH-HUNG; HSU, CHIUN; HONG, RUEY-LONG; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Strategies to Prevent Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Therapy
|
許駿; 魏淑鉁; 鄭安理; 陳培哲; HSU, CHIUN; WEI, SHU-CHEN; CHENG, ANN-LII; CHEN, PEI-JER |
| 國立臺灣大學 |
2009 |
Bortezomib Overcomes Trail Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of P13k/Akt Pathway
|
陳昆鋒; 葉培彥; 許駿; 徐志宏; 盧彥伸; 謝興邦; 陳培哲; 鄭安理; CHEN, KUEN-FENG; YEH, PEI-YEN; HSU, CHIUN; HSU, CHIH-HUNG; LU, YEN-SHEN; HSIEH, HSING-PANG; CHEN, PEI-JER; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Bortezomib Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway
|
陳昆鋒; 葉培彥; 許駿; 徐志宏; 盧彥伸; 謝興邦; 陳培哲; 鄭安理; CHEN, KUEN-FENG; YEH, PEI-YEN; HSU, CHIUN; HSU, CHIH-HUNG; LU, YEN-SHEN; HSIEH, HSING-PANG; CHEN, PEI-JER; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Phase Ii Study of Cetuximab Plus Weekly Cisplatin and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin for the First-Line Treatment of Advanced Gastric Cancer
|
葉坤輝; 徐志宏; 許駿; 林璟宏; 沈盈君; 邱宗傑; 趙毅; 鄭安理; YEH, KUN-HUEI; HSU, CHIH-HUNG; HSU, CHIUN; LIN, CHING-HUNG; SHEN, YING-CHUN; CHIOU, TZEON-JYE; CHAO, YEE; CHENG, ANN-LII |
| 國立臺灣大學 |
2008-06 |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin, Zhong-Zhe; Hsu, Chiun; Chang, Yeun-Chung; Yu, Chong-Jen; Hsu, Chih-Hung; Lin, Chia-Chi; Cheng, Ann-Lii; Yang, Pan-Chyr; Yang, Chih-Hsin; 林宗哲; 許駿; 張允中; 余忠仁; 徐志宏; 林家齊; 鄭安理; 楊泮池; 楊志新 |
| 國立臺灣大學 |
2008 |
Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer
|
Chang, Yu-Ting; Chang, Ming-Chu; Wei, Shu-Chen; Tien, Yu-Wen; Hsu, Chiun; Liang, Po-Chin; Tsao, Po-Nien; Jan, I-Shiow; Wong, Jau-Min |
| 國立臺灣大學 |
2008 |
Expression of Mitosis Regulatory Proteins in Biliary Tract Carcinoma: Correlation with Clinico-Pathological Features and Patient Outcome
|
沈盈君; 胡賦強; 鄭永銘; 張玉憲; 林宗哲; 張明志; 許駿; 鄭安理; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG -MING; CHANG, YU-SHIAHN; LIN, ZONG-ZHE; CHANG, MING-CHIH; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2008 |
Comparison of Hypoplastic Myelodysplastic Syndrome (Mds) with Normo-/ Hypercellular Mds by International Prognostic Scoring System, Cytogenetic and Genetic Studies
|
黃泰中; 柯博升; 唐季祿; 許駿; 陳建源; 蔡偉; 黃聖懿; 姚明; 陳耀昌; 沈銘鏡; 王秋華; 田蕙芬; HUANG, TAI-CHUNG; KO, BO-SHENG; TANG, JIH-LUH; HSU, CHIUN; CHEN, CHIEN-YUAN; TSAY, WOEI; HUANG, SHANG-YI; YAO, MING; CHEN, YAO-CHANG; SHEN, MING- CHING; WANG, CHIU-HWA; TIEN, HWEI-FANG |
| 國立臺灣大學 |
2008 |
A Revisit of Prophylactic Lamivudine for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma: A Randomized Trial
|
許駿; 熊昭; 蘇益仁; 黃偉修; 張明志; 李啟誠; 巫宏博; 田蕙芬; 趙祖怡; 鄭安理; 陳培哲; HSU, CHIUN; HSIUNG, CHAO A.; SU, IH-JEN; HWANG, WEI-SHOU; CHANG, MING-CHIH; LI, CHI-CHENG; WU, HUNG-BO; TIEN, HWEI-FANG; CHAO, TSU-YI; CHENG, ANN -LII; CHEN, PEI-JER |
| 國立臺灣大學 |
2008 |
Expression of the Nuclear Factor Kappa B (Nfkb) P50/P65 Proteins in Hepatocellular Carcinoma (Hcc): Lack of Predictive Value for Response to Thalidomide Treatment
|
許駿; 陳立宗; 趙毅; 沈盈君; 鄭安理; HSU, CHIUN; CHEN, LI-TZONG; CHAO, YEE; SHEN, YING-CHUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2008 |
Forkhead Box Transcription Factor Foxo3a Suppresses Estrogen-Dependent Breast Cancer Cell Proliferation and Tumorigenesis
|
鄭建睿; 許駿; CHENG, CHIEN-JUI; HSU, CHIUN |
| 國立臺灣大學 |
2008 |
Gemcitabine Plus Conventional-Dose Epirubicin Versus Gemcitabine Plus Cisplatin as First-Line Chemotherapy for Stage Iiib/Iv Non-Small Cell Lung Carcinoma-a Randomized Phase Ii Trial
|
許駿; 郭頌鑫; 胡賦强; 鄭安理; 施金元; 余忠仁; 林家齊; 楊泮池; 楊志新; HSU, CHIUN; KUO, SUNG-HSIN; HU, FU-CHANG; CHENG, ANN-LII; SHIH, JIN-YUAN; YU, CHONG-JEN; LIN, CHIA-CHI; YANG, PAN-CHYR; YANG, CHIH-HSIN |
| 國立臺灣大學 |
2008 |
Geographic Difference in Clinical Trial Practice for Advanced Hepatocellular Carcinoma (Hcc): Implications on Trial Design of Global Scale
|
許駿; 沈盈君; 胡賦强; 鄭安理; HSU, CHIUN; SHEN, YING-CHUN; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2008 |
Imaging Adjustment with Dosimetric Verification of Cone-Beam Ct in Head and Neck Cancer Patient
|
許駿; 吳簡坤; 趙曉玲; 王駿瑋; 蔡巧琳; 成佳憲; HSU, CHIUN; WU, JIAN-KUEN; CHAO, HSIAO-LING; WANG, CHUN-WEI; TSAI, CHIAO-LING; CHENG, JASON CHIA-HSIEN |
显示项目 56-105 / 149 (共3页)
<< < 1 2 3 > >>
每页显示[10|25|50]项目
|
